1.44
-0.05 (-3.36%)
| Previous Close | 1.49 |
| Open | 1.49 |
| Volume | 303,708 |
| Avg. Volume (3M) | 1,256,169 |
| Market Cap | 91,016,208 |
| Price / Sales | 0.580 |
| Price / Book | 2.06 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -36.23% |
| Operating Margin (TTM) | -323.11% |
| Diluted EPS (TTM) | -0.880 |
| Quarterly Revenue Growth (YOY) | 44.90% |
| Quarterly Earnings Growth (YOY) | 220.80% |
| Total Debt/Equity (MRQ) | 47.35% |
| Current Ratio (MRQ) | 3.28 |
| Operating Cash Flow (TTM) | -69.62 M |
| Levered Free Cash Flow (TTM) | -40.45 M |
| Return on Assets (TTM) | -26.29% |
| Return on Equity (TTM) | -60.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | MacroGenics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.88 |
|
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.01% |
| % Held by Institutions | 73.84% |
| 52 Weeks Range | ||
| Median | 5.00 (247.22%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 15 Aug 2025 | 5.00 (247.22%) | Buy | 1.58 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Aug 2025 | Announcement | MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities |
| 13 Aug 2025 | Announcement | MacroGenics Appoints Eric Risser as President and Chief Executive Officer |
| 10 Jun 2025 | Announcement | MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement |
| 03 Jun 2025 | Announcement | MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |